Nuvilex (NASDAQ:PMCB – Get Free Report) and Fractyl Health (NASDAQ:GUTS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Profitability
This table compares Nuvilex and Fractyl Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvilex | N/A | 2.13% | 1.69% |
| Fractyl Health | N/A | -4,053.15% | -96.41% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Nuvilex and Fractyl Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvilex | 1 | 0 | 0 | 0 | 1.00 |
| Fractyl Health | 1 | 1 | 4 | 0 | 2.50 |
Institutional and Insider Ownership
34.2% of Nuvilex shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 8.5% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Nuvilex and Fractyl Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvilex | N/A | N/A | $30.66 million | ($1.12) | -0.55 |
| Fractyl Health | $90,000.00 | 1,330.90 | -$140.95 million | ($1.29) | -0.59 |
Nuvilex has higher earnings, but lower revenue than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Nuvilex has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.
Summary
Nuvilex beats Fractyl Health on 7 of the 12 factors compared between the two stocks.
About Nuvilex
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
